Praxbind

Praxbind

idarucizumab

Manufacturer:

Boehringer Ingelheim

Distributor:

Metro Drug

Marketer:

Boehringer Ingelheim
Concise Prescribing Info
Contents
Idarucizumab
Indications/Uses
For adult patients treated w/ dabigatran etexilate (Pradaxa) when rapid reversal of its anticoagulant effects is required: For emergency surgery/urgent procedures & in life-threatening or uncontrolled bleeding.
Dosage/Direction for Use
Restricted to hospital use only. Recommended dose: 5 g. 2nd 5 g dose may be considered if recurrence of clinically relevant & potential re-bleeding would be life-threatening w/ prolonged clotting times or patients requiring 2nd emergency surgery/urgent procedure & have prolonged clotting times.
Special Precautions
Hypersensitivity. Hereditary fructose intolerance. Underlying disease states predisposing to thromboembolic events. Transient proteinuria. Patients on a controlled Na diet. Pregnancy & lactation. Childn.
MIMS Class
Antidotes & Detoxifying Agents
ATC Classification
V03AB37 - idarucizumab ; Belongs to the class of antidotes. Used to reverse anticoagulant effects of dabigatran.
Presentation/Packing
Form
Praxbind soln for inj 50 mg/mL
Packing/Price
50 mL x 2 × 1's (P97,757/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in